Topic: Women’s Health

Nov 12 2013

Pre-surgery drug may help women battle aggressive breast cancer

Disease Management  •  By Miles Varn

The U.S. Food and Drug Administration (FDA) recently granted fast track approval for the biologic, targeted cancer drug pertuzumab, known by the brand name PerjetaR, to treat HER2-positive breast cancer before surgery. The drug had previously been approved last year to treat late stage, HER2-positive breast cancer. Additional larger clinical trials to confirm the results... Read More

Topics: ,